Fred Grossman

2.4k total citations
17 papers, 1.7k citations indexed

About

Fred Grossman is a scholar working on Psychiatry and Mental health, Organic Chemistry and Pharmacology. According to data from OpenAlex, Fred Grossman has authored 17 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 4 papers in Organic Chemistry and 3 papers in Pharmacology. Recurrent topics in Fred Grossman's work include Bipolar Disorder and Treatment (9 papers), Schizophrenia research and treatment (7 papers) and Electroconvulsive Therapy Studies (4 papers). Fred Grossman is often cited by papers focused on Bipolar Disorder and Treatment (9 papers), Schizophrenia research and treatment (7 papers) and Electroconvulsive Therapy Studies (4 papers). Fred Grossman collaborates with scholars based in United States, India and Canada. Fred Grossman's co-authors include Charles L. Bowden, Michelle Kramer, Mariëlle Eerdekens, Akiko Okamoto, Eduard Vieta, Roy H. Perlis, S. Nassir Ghaemi, Keith Karcher, Sumant Khanna and Emma Lee and has published in prestigious journals such as American Journal of Psychiatry, Journal of Allergy and Clinical Immunology and The British Journal of Psychiatry.

In The Last Decade

Fred Grossman

17 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fred Grossman United States 12 1.3k 237 189 163 134 17 1.7k
Margaret Minkwitz United States 17 843 0.6× 77 0.3× 311 1.6× 76 0.5× 29 0.2× 23 1.7k
P. Rosenzweig France 18 307 0.2× 38 0.2× 188 1.0× 46 0.3× 58 0.4× 49 1.1k
Keith Karcher United States 17 1.2k 0.9× 175 0.7× 214 1.1× 264 1.6× 3 0.0× 27 1.5k
Starr L. Grundy United States 12 820 0.6× 97 0.4× 127 0.7× 141 0.9× 57 0.4× 17 994
Robert Croop United States 18 1.4k 1.1× 84 0.4× 118 0.6× 53 0.3× 20 0.1× 106 2.0k
Cristiana Gassmann-Mayer United States 16 1.2k 0.9× 318 1.3× 173 0.9× 162 1.0× 5 0.0× 16 1.6k
Katsuhiko Hagi Japan 19 962 0.7× 63 0.3× 423 2.2× 229 1.4× 5 0.0× 36 1.8k
Myriam Van Moffaert Belgium 15 369 0.3× 51 0.2× 341 1.8× 220 1.3× 49 0.4× 33 815
Judith C. Kando United States 15 741 0.6× 199 0.8× 264 1.4× 135 0.8× 17 0.1× 40 1.2k
Dennis Sweitzer United States 11 672 0.5× 44 0.2× 196 1.0× 142 0.9× 3 0.0× 13 833

Countries citing papers authored by Fred Grossman

Since Specialization
Citations

This map shows the geographic impact of Fred Grossman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred Grossman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred Grossman more than expected).

Fields of papers citing papers by Fred Grossman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fred Grossman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred Grossman. The network helps show where Fred Grossman may publish in the future.

Co-authorship network of co-authors of Fred Grossman

This figure shows the co-authorship network connecting the top 25 collaborators of Fred Grossman. A scholar is included among the top collaborators of Fred Grossman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fred Grossman. Fred Grossman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Brown, Stacey-Ann Whittaker, Camelia Iancu‐Rubin, Elizabeth Burke, et al.. (2022). Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019. Cytotherapy. 24(8). 835–840. 7 indexed citations
2.
Guttman‐Yassky, Emma, Ana B. Pavel, Lisa Zhou, et al.. (2019). GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology. 144(2). 482–493.e7. 160 indexed citations
3.
Rajagopalan, Krithika, et al.. (2016). Review of outcomes associated with restricted access to atypical antipsychotics.. PubMed. 22(6). e208–14. 8 indexed citations
4.
Rajagopalan, Krithika, Mariam Hassan, Ken O’Day, Kellie Meyer, & Fred Grossman. (2013). Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. Journal of Medical Economics. 16(7). 951–961. 8 indexed citations
5.
Khanna, Sumant, Eduard Vieta, Benjamin Lyons, et al.. (2005). Risperidone in the treatment of acute mania. The British Journal of Psychiatry. 187(3). 229–234. 131 indexed citations
6.
Bowden, Charles L., et al.. (2004). Risperidone in Combination With Mood Stabilizers. The Journal of Clinical Psychiatry. 65(5). 707–714. 35 indexed citations
7.
Hirschfeld, Robert M. A., Paul E. Keck, Michelle Kramer, et al.. (2004). Rapid Antimanic Effect of Risperidone Monotherapy: A 3-Week Multicenter, Double-Blind, Placebo-Controlled Trial. American Journal of Psychiatry. 161(6). 1057–1065. 177 indexed citations
8.
Ab, Smulevich, Sumant Khanna, Mariëlle Eerdekens, et al.. (2004). Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. European Neuropsychopharmacology. 15(1). 75–84. 120 indexed citations
9.
Grossman, Fred, et al.. (2004). Developing a professional doctorate in computing. 42–46. 2 indexed citations
10.
Yatham, Lakshmi N., Fred Grossman, Ilse Augustyns, Eduard Vieta, & Arun Ravindran. (2003). Mood stabilisers plus risperidone or placebo in the treatment of acute mania. The British Journal of Psychiatry. 182(2). 141–147. 180 indexed citations
11.
Brodaty, Henry, David Ames, John Snowdon, et al.. (2003). A Randomized Placebo-Controlled Trial of Risperidone for the Treatment of Aggression, Agitation, and Psychosis of Dementia. The Journal of Clinical Psychiatry. 64(2). 134–143. 348 indexed citations
12.
Jeste, Dilip V., Yoram Barak, Subramoniam Madhusoodanan, Fred Grossman, & Georges M. Gharabawi. (2003). International Multisite Double-Blind Trial of the Atypical Antipsychotics Risperidone and Olanzapine in 175 Elderly Patients With Chronic Schizophrenia. American Journal of Geriatric Psychiatry. 11(6). 638–647. 62 indexed citations
13.
Perlis, Roy H., Fred Grossman, S. Nassir Ghaemi, Akiko Okamoto, & Charles L. Bowden. (2002). Combination of a Mood Stabilizer With Risperidone or Haloperidol for Treatment of Acute Mania: A Double-Blind, Placebo-Controlled Comparison of Efficacy and Safety. American Journal of Psychiatry. 159(7). 1146–1154. 291 indexed citations
14.
Grossman, Fred, et al.. (1999). A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. Journal of Affective Disorders. 56(2-3). 237–243. 44 indexed citations
15.
16.
Grossman, Fred. (1998). A Review of Anticonvulsants in Treating Agitated Demented Elderly Patients. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 18(3). 600–606. 23 indexed citations
17.
Grossman, Fred, Husseini K. Manji, & William Z. Potter. (1993). Platelet α2-adrenoreceptors in depression: a critical examination. Journal of Psychopharmacology. 7(1_suppl). 4–18. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Margaret Minkwitz Breakdown of academic impact, for papers by P. Rosenzweig Breakdown of academic impact, for papers by Keith Karcher Breakdown of academic impact, for papers by Starr L. Grundy Breakdown of academic impact, for papers by Robert Croop Breakdown of academic impact, for papers by Cristiana Gassmann-Mayer Breakdown of academic impact, for papers by Katsuhiko Hagi Breakdown of academic impact, for papers by Myriam Van Moffaert Breakdown of academic impact, for papers by Judith C. Kando Breakdown of academic impact, for papers by Dennis Sweitzer
Rankless by CCL
2026